Wesbury: Shrinking 4Q GDP `Kind of a Head Fake'

Jan. 30 (Bloomberg) -- Brian Wesbury, chief economist at First Trust Advisors, discusses the fourth-quarter GDP report which saw the U.S. economy shrink 0.1 percent as government spending on defense fell the most since 1972. He speaks on Bloomberg Television's "In The Loop."

Merck KgaA, Pfizer Cancer Drug to Cost $13,000 a Month
08:33 - Pfizer and Merck KGaA’s cancer immunotherapy won approval from U.S. regulators for patients with a rare form of skin cancer, and the companies plan to sell the drug for $13,000 a month. Merck KgaA CEO Stegfan Oschmann speaks on "Bloomberg Daybreak Europe." (Source: Bloomberg)
  • Aviva's Diebel Sees No Macro Impact From Healthcare Bill
  • Italy Junior Minister Sees Brexit as EU Opportunity
  • French Presidential Race Takes an Inflammatory Turn